Nacresertib

N/A

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameNacresertib
Drug Alias NameMY-004567MY004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsPsoriasisGlomerulonephritis, IGAArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Meiyue Biotechnology Dev Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAbbvie IncShanghai Meiyue Biotechnology Dev Co LtdWuhan Createrna Science and Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisGlomerulonephritis, IGAArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A